AN2 Therapeutics (ANTX) Assets Average (2022 - 2026)

AN2 Therapeutics (ANTX) has reported Assets Average for 5 consecutive years, with $74.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average fell 13.83% year-over-year to $74.7 million; the TTM figure through Mar 2026 stood at $74.7 million (down 13.83% YoY), while the FY2025 annual figure was $77.0 million, down 33.27% from the prior year.
• Assets Average grew to $74.7 million in Q1 2026 per ANTX's latest filing, from $64.6 million in the prior quarter.
• Across five years, Assets Average topped out at $146.3 million in Q4 2023 and bottomed at $64.6 million in Q4 2025.
• Historically, Assets Average has averaged $101.1 million across 5 years, with a median of $96.8 million in 2023.
• Annual changes were most pronounced in 2023 — Assets Average surged 37.63% — and 2024, when it slumped 35.13%.
• AN2 Therapeutics' Assets Average stood at $106.3 million in 2022, then surged by 37.63% to $146.3 million in 2023, then plunged by 35.13% to $94.9 million in 2024, then sank by 31.93% to $64.6 million in 2025, then climbed by 15.68% to $74.7 million in 2026.
• Business Quant data shows ANTX's Assets Average at $74.7 million in Q1 2026, $64.6 million in Q4 2025, and $71.5 million in Q3 2025.